About Inhibrx Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://inhibrx.com/
Frequently Asked Questions
What is the 52-week range for INBX?
The 52-week high is $155.29 and the 52-week low is $28.16.
What is the P/E ratio for INBX?
The P/E ratio data is currently unavailable.
What is the dividend yield for INBX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -269.56%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -5465.64%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 143.75.
Analyst Recommendation Trends
Wall Street analyst consensus for INBX over the last few months:
Latest INBX News
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
Inhibrx Biosciences (INBX) has drawn investor attention after a sharp move in the share price. The US$101.71 close now sits alongside a year-to-date gain of about 35%. Recent trading has been choppy, with a 1-day share price return of 2.11% following a 7-day share price return that fell 9.22% and a 30-day share price return down 17.58%. Despite this, Inhibrx Biosciences still shows a year-to-date share price return of 35.54% and a very large 1-year total shareholder return of 214.79%. This...
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Lappe's purchase through family trusts boosts his beneficial ownership to 950,000 shares, or 6% of outstanding equity, as Inhibrx trades near $114 following a 293% gain over the past year.
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx (INBX) updates: ozekibart & INBRX-106 show strong rare cancer and immuno-oncology data; FDA BLA due Apr 2027.
There are notable gap-ups and gap-downs in today's session.
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer. Data from the HexAgon study showed a confirmed objective response rate of 48.
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 a
Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-28 | Lappe Mark | +3,000 | $101.702 | $305,106 |
| 2026-09-28 | Lappe Mark | +1,500 | $98.8803 | $148,320 |
| 2026-09-25 | Lappe Mark | +2,176 | $99.5988 | $216,727 |
| 2026-09-25 | Lappe Mark | +3,324 | $98.8659 | $328,630 |
| 2026-09-23 | Kayyem Jon Faiz | +5,000 | $100 | $500,000 |
| 2026-09-16 | Kayyem Jon Faiz | +5,000 | $100 | $500,000 |
| 2026-09-15 | MANHARD KIMBERLY | -500 | $105.05 | $52,525 |
| 2026-09-14 | MANHARD KIMBERLY | -500 | $110.26 | $55,130 |
| 2026-09-11 | MANHARD KIMBERLY | -500 | $111.775 | $55,888 |
| 2026-09-09 | MANHARD KIMBERLY | -500 | $115.795 | $57,898 |
| 2026-09-08 | Kayyem Jon Faiz | +5,000 | $113.516 | $567,580 |
| 2026-09-08 | Lappe Mark | +9,681 | $112.2819 | $1,087,001 |
| 2026-09-08 | Lappe Mark | +1,219 | $111.8805 | $136,382 |
| 2026-09-08 | Lappe Mark | +500 | $108.235 | $54,118 |
| 2026-09-08 | Lappe Mark | +1,100 | $107.1239 | $117,836 |
| 2026-09-08 | Lappe Mark | +6,605 | $100.6388 | $664,719 |
| 2026-09-08 | Lappe Mark | +5,895 | $99.2948 | $585,343 |
| 2026-09-08 | FORSYTH DOUGLAS | +2,500 | $114.6469 | $286,617 |
| 2026-09-08 | MANHARD KIMBERLY | -500 | $115.14 | $57,570 |
| 2026-06-03 | Vuori Kristiina MD | +10,000 | - | - |
| 2026-06-03 | Kayyem Jon Faiz | +10,000 | - | - |
| 2026-06-03 | FORSYTH DOUGLAS | +10,000 | - | - |
| 2026-06-03 | MANHARD KIMBERLY | +10,000 | - | - |
| 2026-06-03 | Vuori Kristiina MD | +15,000 | - | - |
| 2026-06-03 | Kayyem Jon Faiz | +15,000 | - | - |
| 2026-06-03 | FORSYTH DOUGLAS | +15,000 | - | - |
| 2026-06-03 | MANHARD KIMBERLY | +15,000 | - | - |
| 2026-04-24 | Matly David | +50,000 | - | - |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | -25,042 | $32.25 | $807,605 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | -16,315 | $32.25 | $526,159 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | -308,643 | $32.25 | $9,953,737 |